regarding cataplexy. In 1 study, 6 these questions were administered to 983 patients with a variety of sleep disorders entering the Stanford Sleep Disorder Clinic. Of these, 63 were determined to have clear-cut cataplexy by the sleep specialist, and the other 920 patients served as control subjects without narcolepsy. The researchers determined that positive emotions, such as laughter, elation, and joking, were common triggers of cataplexy. Receiver operating curve analysis indicated that telling and hearing a joke, anger, and laughter were the 3 triggers most likely to differentiate clear-cut cataplexy.
The present study was designed as an extension of our previous study "Characterizing the emotions that trigger cataplexy," 7 in which we used a modified version of the published 51-item cataplexy questionnaire that had been validated by Anic-Labat. 6 We found laughter to be the trigger most likely to provoke cataplexy. Physical signs of a cataplexy episode were examined as well. Two of these features, slurred speech and ability to hear, were the strongest predictors.
The CETQ (Cataplexy Emotional Trigger Questionnaire) was developed to aid patient comprehension and included questions based on lifetime experience of these symptoms. Positive predictive value (PPV) and negative predictive value (NPV) were estimated for each question.
METHODS
This study was reviewed and approved by the Mayo Clinic Institutional Review Board and completed in the Mayo Sleep Disorders Center. Patients with potential narcolepsy were screened by a physician investigator (MHS) to ensure that they met Mayo diagnostic criteria for laboratory-confirmed narcolepsy with cataplexy. 8 The control group comprised patients with obstructive sleep apnea syndrome (OSA), diagnosed by polysomnography using the International Classification of Sleep Disorders criteria. 2 We excluded patients with history of seizure disorders or dementia. Patients either were enrolled at the time of office visits or were mailed the questionnaire with a letter of invitation to participate. The questionnaire ( Figure) consisted of 1 item that required a yes or no response followed by 4 follow-up questions if the first question was answered affirmatively.
The sample-size calculation for this study was based on a 95% exact binomial confidence interval. Assuming a sensitivity and specificity of 95% and 75 patients per group, the width of each 2-sided 95% exact binomial confidence interval would be approximately 12%. Sensitivity, specificity, and the area under the receiver-operating characteristic curve (AUC) were computed individually for each question. Ninety-five percent confidence We are asking these questions as part of a narcolepsy research project, and your participation would be appreciated, regardless of whether or not you have narcolepsy. Your access to medical care at the Mayo Clinic will not be affected by your request not to complete this form. Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness. Symptoms can also include having vivid dreams, being unable to move for a short time after awakening, and/or suddenly losing muscle control because of strong emotions. Below are some questions about cataplexy symptoms. Please answer these questions about your sudden muscle weakness. intervals were calculated for sensitivity and specificity using the exact binomial distribution. For AUC, the method described by Delong et al was used to calculate the standard error for calculating the 95% confidence interval. 8 Assuming cataplexy prevalence is 0.05 in a tertiary sleep disorder center, the PPV and NPV were estimated individually for each question. Confidence intervals for PPV and NPV were computed using the bootstrap. If a participant responded no to question 1, responses to questions 2-5 were set to no. Patient characteristics were compared using the 2-sample rank sum test for continuous variables and the χ 2 test for categorical variables. In all cases, 2-sided tests with p values ≤ .050 were considered statistically significant.
RESULTS
There were 156 subjects who completed the questionnaire, 78 with narcolepsy and cataplexy and 78 with OSA. The mean age of subjects with narcolepsy and cataplexy was 53.5 ± 18.4 (range 20-84) years old compared with 58.8 ± 10.7 (range 33-85) years old for control subjects (p = .158). There were 45 women (58%) in the narcolepsy with cataplexy group and 28 women (36%) in the OSA group (p = .006). Twenty-six of the narcolepsy with cataplexy subjects (33%) had testing for hypocretin-1 levels in the cerebrospinal fluid. Of these, 23 (88%) had less than 110 pg/mL of hypocretin-1. Table 1 displays the diagnostic results of the 5-item cataplexy questionnaire. Question 1, "Have you ever experienced sudden muscle weakness when you laugh?" had a sensitivity of 0.94 (95% CI: 0.86, 0.98) and a specificity of 0.99 (95% CI: 0.93, 1.0) with an AUC of 0.96 (95% CI: 0.93, 0.99). Question 2, "During episodes of your muscle weakness, can you hear?" had a sensitivity of 0.90 (95% CI: 0.81, 0.95), specificity of 0.99 (95% CI 0.93, 1.0, and AUC of 0.94 (95% CI 0.91, 0.98). Table 2 shows PPVs and NPVs for each question of the 5-item questionnaire. Assuming a prevalence of 0.05, the NPV is 1.0 for question 1 and 0.99 for questions 2 through 5. The PPV is 0.79 (95% CI: 0.55, 1.0) for question 1 and 0.79 (95% CI: 0.54, 1.0) for question 2. Note, due to the lack of potentially false-positive responses, the PPV was 1.0 for question 5, "During your episodes of muscle weakness, is your whole body affected?" The addition of the other 4 questions, in the context of question 1, did not improve specificity, AUC, NPV, or PPV but did provide useful confirmatory data.
Of 53 subjects who had narcolepsy with cataplexy who had undergone HLA testing, 45 (85%) were positive for HLA DQB1*0602. Of these 45 subjects, 1 (2%) answered no to question 1. Of the 8 participants who were HLA DQB1*0602 negative, 3 (37%) answered no to question 1. One subject with cataplexy who did not undergo HLA testing answered no to question 1. One control subject answered yes to question 1. Table 3 summarizes the findings in these subjects with apparent false-negative orpositive results. Laughter was not listed as a precipitant emotion for any of the subjects with false-negative responses. The single control subject with a false positive denied any symptoms of cataplexy at a sleep consultation. None of the 6 subjects had been tested for hypocretin-1 levels in the cerebrospinal fluid.
DISCUSSION
The most significant finding is that a practical cataplexy screen will enhance recognition of cataplexy in a sleep-center setting. The questionnaire discriminated patients with cataplexy from controls with excellent specificity and sensitivity. Unlike previously published cataplexy questionnaires, in which usage is limited due to the length of the survey, this survey has the potential to be more widely used because of its brevity. The practical screening questions from this survey can easily be incorporated into clinical practice, as well as into more-general screening sleep questionnaires. Another important finding of the study was the fact that our nonnarcoleptic control group did not demonstrate the high rate of cataplexy-like symptoms that has been reported in previous studies. 6,10,-12 This finding suggests that the questionnaire differentiates definite cataplexy from other nonspecific forms of muscle weakness that have been found in previous epidemiologic This strength of this study is related to the design. It was validated with patients who have a confirmed laboratory-based diagnosis of narcolepsy with cataplexy. This project used a different statistical approach from those used in previous papers. No other screen for cataplexy to date has been validated in terms of PPV/ NPV. The PPV/PPN concept, which is familiar to many clinicians, readily conveys the precision of this screening instrument.
The pilot nature of the study with recruitment restricted to patients already seen in a sleep center contributes to the study's limitations. The study protocol precluded enrollment of a larger more-diverse patient population with undiagnosed sleep disorders. The survey has not yet been tested with patients other than those with OSA or narcolepsy with cataplexy. Prior to embarking on a study with much larger sample size (including patients with undiagnosed narcolepsy), we wished to assess the validity of the questionnaire, affirming that the questions discriminated between patients with narcolepsy with cataplexy (not naïve to cataplexy) and patients with other sleep disorders (OSA naïve to cataplexy). Patients with narcolepsy with cataplexy vary in their own awareness of cataplexy, depending on the severity of symptoms, frequency of triggers, and duration of disease, as well as their level of education about narcolepsy. Additional studies need to be conducted with larger sample sizes of patients with and without undiagnosed cataplexy to further demonstrate the effectiveness of a brief screening tool. To recruit a sufficient number of patients with narcolepsy with cataplexy prior to a diagnosis, a multicenter study may be necessary.
Asking patients who have never had cataplexy about this unusual experience is difficult. Those patients sometimes have difficulty understanding the description of cataplexy explaining that these symptoms were unfamiliar to them. Patients without cataplexy could have potentially misinterpreted the described muscle weakness and attributed these symptoms to other conditions. However, based on the data, it does not appear that this occurred because the number of false positives in the OSA control group was very low. The single patient with OSA who responded positively to the question has not been determined to have any symptoms of narcolepsy based on sleep-center consultation. Patients with narcolepsy with cataplexy did not appear to have difficulty comprehending the survey's depiction of cataplexy. The study had sex differences between the cataplexy and control group. This is not unexpected, given the higher prevalence of OSA in men versus women.
Enigmatic patients with atypical cataplexy will remain challenging, and, for those patients, surveys are not particularly helpful. 13 This subset of patients will continue to require careful assessment by clinicians with considerable experience with narcoleptic patients. Nonetheless, if this tool improves or advances the recognition of patients with classic cataplexy, this study creates a needed new diagnostic tool.
Narcolepsy identification, research, and clinical interventions continue to be challenging. Having brief but reliable tools that can be used in patients with undifferentiated diagnoses in a sleep disorder center, specialty practice (neurology, psychiatry, pulmonary), and primary care is critical to reduce the rate of underdiagnosis of narcolepsy. Once the patient endorses items on a questionnaire suggestive of cataplexy, the expense and logistics of laboratory testing are more justified. 
